Catalyst Pharmaceuticals (CPRX): Valuation Insights After Strong Q3 Results and New Share Buyback Program

Simply Wall St.11-09

Catalyst Pharmaceuticals (CPRX) shares drew fresh attention after the company reported an impressive third quarter. Revenue and earnings both climbed sharply year over year. Management also raised ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582892083?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-09 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582892083","market":"us","top_or_hot":-1,"title":"Catalyst Pharmaceuticals (CPRX): Valuation Insights After Strong Q3 Results and New Share Buyback Program","media":"Simply Wall St.","content":"<div>\n<p>Catalyst Pharmaceuticals (CPRX) shares drew fresh attention after the company reported an impressive third quarter. Revenue and earnings both climbed sharply year over year. Management also raised ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-valuation-insights-after-stron\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catalyst Pharmaceuticals (CPRX): Valuation Insights After Strong Q3 Results and New Share Buyback Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatalyst Pharmaceuticals (CPRX): Valuation Insights After Strong Q3 Results and New Share Buyback Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-09 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-valuation-insights-after-stron><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Catalyst Pharmaceuticals (CPRX) shares drew fresh attention after the company reported an impressive third quarter. Revenue and earnings both climbed sharply year over year. Management also raised ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-valuation-insights-after-stron\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-valuation-insights-after-stron","article_id":"2582892083","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-valuation-insights-after-stron","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582892083","pubTimestamp":1762694956,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Catalyst Pharmaceuticals (CPRX) shares drew fresh attention after the company reported an impressive third quarter. Revenue and earnings both climbed sharply year over year. Management also raised full-year revenue guidance, reinforcing confidence in future growth.\nSee our latest analysis for Catalyst Pharmaceuticals.\nMomentum has picked up for Catalyst Pharmaceuticals in recent months, with third-quarter earnings, upbeat revenue guidance, and a new $200 million share buyback sparking...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CPRX":"Catalyst Pharmaceutical Partners","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D"},"translate_title":"Catalyst Pharmaceuticals(CPRX)：强劲的第三季度业绩和新股回购计划后的估值见解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1.5},"content_text":"Catalyst Pharmaceuticals (CPRX) shares drew fresh attention after the company reported an impressive third quarter. Revenue and earnings both climbed sharply year over year. Management also raised full-year revenue guidance, reinforcing confidence in future growth. See our latest analysis for Catalyst Pharmaceuticals. Momentum has picked up for Catalyst Pharmaceuticals in recent months, with third-quarter earnings, upbeat revenue guidance, and a new $200 million share buyback sparking investor enthusiasm. The stock’s 1-year total shareholder return is still down 10.6%, but steady product growth and strong financials have fueled a resilient 8.7% three-month share price return and contributed to a 46% total return over three years. If you’re interested in what else is catching investors’ attention in healthcare, check out the next wave of innovation with our See the full list for free. But with shares still trading well below analyst price targets and strong fundamentals powering recent results, is Catalyst Pharmaceuticals an undervalued growth story waiting to be discovered, or has the market already factored in its momentum? AdvertisementMost Popular Narrative: 37.6% Undervalued  Catalyst Pharmaceuticals trades well below the most popular fair value estimates, with its last closing price far from consensus expectations. The crowd believes the gap is driven by tangible catalysts, not just sentiment.\n    Significant upside exists from expanding FIRDAPSE's addressable patient pool by improving rare cancer-associated LEMS diagnosis. This is influenced by updated NCCN guidelines, wider access to frictionless VGCC antibody testing, and targeted oncology education. With 90% of this segment still undiagnosed, this lays a foundation for sustained, above-market revenue growth in 2026 and beyond as more patients are identified and treated.\n   Read the complete narrative.  Curious about the hidden metrics behind such a bold valuation gap? There is one assumption here that could completely reshape how you think about future growth and profitability. The full narrative spells out the Wall Street logic and the numbers that other investors might be missing.\n Result: Fair Value of $34.29 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, heavy reliance on FIRDAPSE and the impact of potential generic competition could quickly change the outlook for Catalyst Pharmaceuticals. Find out about the key risks to this Catalyst Pharmaceuticals narrative.  Build Your Own Catalyst Pharmaceuticals Narrative If you see the story differently or want to dig into the numbers firsthand, you can build and share your own take in just a few minutes, all with Do it your way. A good starting point is our analysis highlighting 5 key rewards investors are optimistic about regarding Catalyst Pharmaceuticals. Looking for more investment ideas? Gain an edge by expanding your watchlist with fresh opportunities that others might be missing. Your next great investment could be just a click away if you act now.  Uncover companies trading below their potential and start with these 874 undervalued stocks based on cash flows before the crowd catches on. Generate passive income by checking out these 16 dividend stocks with yields > 3% offering yields that can strengthen your portfolio’s returns. Stay ahead in tomorrow’s fintech revolution by tapping into these 82 cryptocurrency and blockchain stocks that are redefining digital finance and blockchain innovation.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582892083","isCrawlerRequest":true}